Novo Nordisk Hunts for Deals After Losing Metsera to Pfizer
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
/ 6 items
#TERN↓
TERN-701 Shows 64% Response Rate in Hard-to-Treat Leukemia
Terns Pharmaceuticals (TERN) announces encouraging Phase 1 results for TERN-701, showing 64% response rates in relapsed/refractory chronic myeloid leukemia patients with favorable safety profile.
William Blair Upgrades Terns Pharmaceuticals to Outperform After Strong TERN-701 Data
William Blair upgraded Terns Pharmaceuticals (TERN) to Outperform following impressive Phase 1 CARDINAL trial results of TERN-701 in chronic myeloid leukemia, showing a 75% overall major molecular response rate and strong safety profile.
Terns Pharma Abandons Obesity Drug After Disappointing Trial Results
Terns Pharmaceuticals halts development of oral GLP-1 obesity treatment TERN-601 after Phase 2 trial shows modest weight loss and liver safety concerns.
Truist Sees Major Upside in Terns Pharmaceuticals Stock
Truist initiates Terns Pharmaceuticals with Buy rating and $20 target, citing promising blood cancer drug and oral GLP-1 treatment potential.
Pharma Giant Roche Buys 89bio for up to $3.5 Billion to Fight Fatty Liver Disease
Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.